AM-Pharma
PrivateLast Round
Series E
Extension
Mar 31, 2020
Total Funding Raised
$321.53M
Company Overview
AM-Pharma is a biopharmaceutical company developing proprietary recombinant human alkaline phosphatase therapeutics for the treatment of severe medical conditions such as acute kidney injury, inflammatory bowel disease, and hypophosphatasia.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AM-Pharma Comparables
Compare AM-Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alloksys Life Sciences B.V. | 86% | |
| Guard Therapeutics International AB | 86% | |
| Renibus Therapeutics | 85% | |
AM-Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E Extension | Mar 31, 2020 | ||||
| Series E | Jul 16, 2019 | ||||
| Corporate Funding | May 11, 2015 | ||||
| VC Round | Sep 11, 2014 | ||||
| Series D | Sep 13, 2011 | ||||
Debt | Mar 19, 2009 |
Key People
Founding team and executive leadership
AM-Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B, Series C, Series E, Series D |
| EQT Life Sciences | Series E Extension, Series E |
| Idinvest Partners | VC Round, Series E, Series E Extension, Series D |
| Forbion | Series C, Series E, Series E Extension, Series D |
| BB Biotech | VC Round, Series D |
| Andera Partners | Series E Extension, Series E |
| Ysios Capital | VC Round, Series E, Series E Extension, Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 31, 2020
$27M round led by Blue Owl Capital.
- Jul 16, 2019
$133M round led by Andera Partners and EQT Life Sciences.
AM-Pharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AM-Pharma's valuation, stock price, and market status.